Koers RXi Pharmaceuticals Corp Nasdaq
Aandelen
US74979C5013
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 75 mln. 69,01 mln. | Marktkapitalisatie | 3,36 mln. 3,09 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -9 mln. -8,28 mln. | Nettowinst (verlies) 2025 * | 47 mln. 43,25 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,04 x |
K/w-verhouding 2024 * |
-0,43
x | K/w-verhouding 2025 * |
0,21
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,41% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Director/Board Member | 73 | 02-05-22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18-04-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,63% | 50,85 mld. | |
-0,09% | 42,82 mld. | |
+49,62% | 42,03 mld. | |
-4,96% | 29,55 mld. | |
+11,18% | 26,11 mld. | |
-21,95% | 19,13 mld. | |
+8,61% | 13,05 mld. | |
+28,31% | 12,16 mld. | |
+24,73% | 12,08 mld. |